Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.44 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL223345 | 0.96 | CA4 (0.47) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL33936 | 0.96 | CA4 (0.47) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL5689090 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL15842973 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL4661565 | 0.92 | — | — | |
| Glycine SCHEMBL4728488 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL5187484 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL2161269 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL3121145 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL5943682 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166533-A1 | SYNERGISTIC COMPOSITIONS AND METHODS FOR POTENTIATING ANTI-OXIDATIVE ACTIVITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZAT (IL) | 2016-06-16 | — | — | US | claimed |
| US-9060959-B2 | Synergistic compositions and method for potentiating anti-oxidative activity | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2015-06-23 | — | — | US | claimed |
| CN-101970008-B | Palatable solid composition comprising antacid and saliva stimulant | BAYER CONSUMER CARE AG | 2013-10-30 | — | — | CN | claimed |
| CN-101970008-A | Palatable solid composition comprising antacid and saliva stimulant | BAYER CONSUMER CARE AG | 2011-02-09 | — | — | CN | claimed |
| EP-2262534-A1 | PALATABLE SOLID COMPOSITION COMPRISING ANTACID AND SALIVA STIMULANT | Bayer Consumer Care AG (CH) | 2010-12-22 | — | — | EP | claimed |
| WO-2009112156-A1 | PALATABLE SOLID COMPOSITION COMPRISING ANTACID AND SALIVA STIMULANT | BAYER CONSUMER CARE AG (CH) | 2009-09-17 | — | — | WO | claimed |
| WO-2009095210-A1 | COMPOSITION COMPRISING AN ANTACID AND A H2-ANTAGONISTS | BAYER CONSUMER CARE AG (CH) | 2009-08-06 | — | — | WO | claimed |
| WO-2009067234-A1 | COMPOSITION AND METHOD FOR TREATMENT OF ORAL INFLAMMATION AND ULCERATION | ZAHRA MOHAMMED (US) | 2009-05-28 | — | — | WO | claimed |
| US-20090130232-A1 | Composition and method for treatment of oral inflammation an ulceration | ZAHRA MOHAMMED | 2009-05-21 | — | — | US | claimed |
| EP-1857102-A1 | Folic acid supplement | Drugtech Corporation (US) | 2007-11-21 | — | — | EP | claimed |
| EP-0600725-B1 | Pharmaceutical compositions containing a guanidinothiazole and antacids | MCNEIL PPC INC (US) | 1997-09-17 | — | — | EP | claimed |
| EP-0578732-B1 | CHEWABLE ANTACID COMPOSITIONS | PROCTER & GAMBLE (US) | 1996-06-19 | — | — | EP | claimed |
| EP-0578768-B1 | INGESTIBLE PHARMACEUTICAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL TRACT DISTRESS | PROCTER & GAMBLE (US) | 1995-09-27 | — | — | EP | claimed |
| EP-0600725-A1 | Pharmaceutical compositions containing a guanidinothiazole and antacids | McNEIL-PPC, INC. (US) | 1994-06-08 | — | — | EP | claimed |
| EP-0578732-A1 | CHEWABLE ANTACID COMPOSITIONS. | PROCTER & GAMBLE (US) | 1994-01-19 | — | — | EP | claimed |
| EP-0578768-A1 | INGESTIBLE PHARMACEUTICAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL TRACT DISTRESS. | PROCTER & GAMBLE (US) | 1994-01-19 | — | — | EP | claimed |
| US-5244670-A | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress | THE PROCTER & GAMBLE COMPANY (US) | 1993-09-14 | — | — | US | claimed |
| WO-1992017164-A1 | INGESTIBLE PHARMACEUTICAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL TRACT DISTRESS | THE PROCTER & GAMBLE COMPANY (US) | 1992-10-15 | — | — | WO | claimed |
| WO-1992017161-A1 | CHEWABLE ANTACID COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-10-15 | — | — | WO | claimed |
| US-4937076-A | CHOCOLATE OR HYDROGENATED TALLOW AS COATING AND BINDER; STORAGE STABILITY | COMBE INCORPORATED (US) | 1990-06-26 | — | — | US | claimed |